TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total overactive bladder symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEM (Total Energy Metabolism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVC exit-site infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteremia rates
Endpoint domain: Adverse events/effects
Primary endpoint: secondary enucleation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase in asthma attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in asthma medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduce high blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower serum cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kofoed ankle score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐rated lower limb function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of phytopharmaceuticals on onychomycosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vitreous hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: body mass index differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in HIV-1 RNA at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bother
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motility of spermatozoa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: number of spontaneous pregnancies
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: False positive mode switch caused by FFS
Endpoint domain: Adverse events/effects
Primary endpoint: Medical burden (cardiovascular illness)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: primary outcome contacts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in meperidine usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in midazolam usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient scores for overall sedation and pain level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma levels of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of apoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of Ox-LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean hemoglobin A1c concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first use of morphine PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate in N0 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metformin efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mycophenolic acid area under the time‐concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mycophenolic acid plasma clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: postprandial triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk for alcohol and substance use
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Risk for sensation seeking
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Greater physical health risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global DNA hypomethylation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uracil misincorporation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life index (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of antipyretic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Underestimation of true bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean length of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of excess weight loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of iron deficiency
Endpoint domain: Adverse events/effects
Primary endpoint: Mean peak serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlamydia testing rates among women making preventive care visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of pain medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: healthcare-associated infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal neurobehavioural parameters suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in Unified Parkinson's Disease Rating Scale motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in cardiovascular prevention services
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patient health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of bronchi and carina injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Time of Uniblocker placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Optimal depth of Uniblocker placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Power spectral value of the α band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of RTS,S/AS02A
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity for anti-circumsporozoite protein antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity for anti-hepatitis-B surface antigen response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success of SCS compared to reoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for further revascularization procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chair-stand time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Adherence Rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Compliance with the bowel preparation regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in VSC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pocket depth values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bleeding on probing values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS part I score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schwab and England scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of morphine required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification accuracy of participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological inflammatory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PASE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLACC scores post venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIPS score post venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying time post venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Approximal pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Approximal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional reach test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved 5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of episodes away from home per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: satisfaction with transport
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: associated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of ramosetron to granisetron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events within 24 h
Endpoint domain: Adverse events/effects
Primary endpoint: overall complete clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discontinuation of treatment due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the median number of incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slowed growth in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cycle control (scheduled withdrawal bleedings)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Pressure (PP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life scale by FACT-Cx
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EPIC-CP scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acute radiation injury classification
Endpoint domain: Adverse events/effects
Primary endpoint: Delta CRP and IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody response against H1N1 influenza strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: heavy drinking probabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reversion to episodic migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isometric and dynamic muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle activity during unipedal stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of granuloma around the gastrostoma
Endpoint domain: Adverse events/effects
Primary endpoint: Mean side-to-side difference in anterior knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC subjective knee evaluation results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of left‐sided adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of 17-OHP and TSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuation of epidural sufentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal pressure of SO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of bile duct stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma detection rate (ADR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative risk (RR) of missing adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acid-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sensitivity in detecting cartilage abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of arthroscopic procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of polyps detected per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of adenomas detected per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LV dysfunction with or without heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asymptomatic LV dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak APAP-CYS concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small bowel permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean global IBS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of instrumentation sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Direct costs of instrumentation sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Favorable neurologic outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality percentage
Endpoint domain: Mortality/survival
Primary endpoint: Daily variations of ICP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reporting 30% or more reduction in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity after meal ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days to reach feeding volume end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Responsiveness to change of GSFQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: grade 2 stomatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infections caused by melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean number of sucks detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of total mortality, cerebral infarction, embolism, bleeding, heart failure, and physical/psychological disability
Endpoint domain: Mortality/survival
Primary endpoint: Duration of tinnitus suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cox menstrual score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ibuprofen tablets consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Denture plaque scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Denture-induced stomatitis prevalence reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingivitis scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hourly bupivacaine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full ban on smoking in the home
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EC(50) for propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat coronary revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability for critical reading of research reports
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Posttraumatic growth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention of fissure sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Aβ42 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality associated with high plasma Aβ42 levels
Endpoint domain: Mortality/survival
Primary endpoint: Mean annual loss in lumbar BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean annual increase in BMD in postmenopausal women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: umbilical artery pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: umbilical artery PCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: umbilical artery base deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: OGTT disposition index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T2D incidence reduction
Endpoint domain: Mortality/survival
Primary endpoint: Probability of achieving normoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in unintended forward penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrement of Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of Flow-Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone mineral density of the fractured lateral malleolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tempo of bone maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height gain per bone-age year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral and hepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days to surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of condom protected intercourse acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of unprotected vaginal sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of intra‐oesophageal acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Significant reduction in SI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fewer acute asthma events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: fewer lost school days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: lower symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol impairment on behavioral control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes